Reuters logo
BRIEF-Zogenix announces new data for ZX008 in treatment of seizures
December 5, 2016 / 1:17 PM / a year ago

BRIEF-Zogenix announces new data for ZX008 in treatment of seizures

Dec 5 (Reuters) - Zogenix Inc

* Zogenix announces new efficacy and safety data for zx008 in treatment of seizures in lennox gastaut syndrome & dravet syndrome

* Zogenix-New data shows effectiveness, cardiovascular-related safety for patients treated with zx008 as adjunctive therapy for seizures associated with lgs

* Zogenix inc - new data showed continued effectiveness, safety for on-going open-label patients with dravet syndrome in patients treated with zx008

* Zogenix inc - treatment with low-dose fenfluramine continues to be generally well-tolerated

* Zogenix inc - zogenix’s phase 3 program for dravet syndrome continues to enroll patients in u.s. And internationally

* Zogenix inc - expects availability of phase 3 top-line data in dravet syndrome in q2 of 2017

* Zogenix inc - potential regulatory submissions for approval for zx008 to occur by year-end 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below